The instrument yields :
Blinded patient data from the randomized, double‑blind, phase‑2 trial of lotiglipron (NCT05579977) in adults with obesity without diabetes were used to establish MWPC thresholds for the Physical Function composite.
Highly sensitive to weight changes; scores typically improve by 13.5 to 16.6 points following clinically meaningful weight loss.
This article provides a comprehensive overview of what the IWQOL-Lite-CT is, where to find the official PDF, how to score it accurately, and why it has become an indispensable tool in modern clinical trials. iwqol-lite-ct pdf
This structure gives researchers a two-level view: a detailed look at specific aspects and an overall summary via the , which combines all items for a complete picture. Scores are transformed to a 0-100 scale for easy interpretation, where higher scores represent better weight-related quality of life .
Do you need help finding ?
To address this gap, two were conducted to inform the development of a version optimized for use in obesity clinical trials. The resulting IWQOL-Lite-CT was developed and validated according to the U.S. Food and Drug Administration's (FDA) guidance on patient‑reported outcomes . Importantly, FDA qualification is being sought for the IWQOL-Lite-CT for use in clinical trials to support product‑approval and labeling claims. The instrument yields : Blinded patient data from
| Option | Best For | Key Features | |--------|----------|--------------| | | Early‑phase studies, low‑tech environments | Print‑ready PDF, manual scoring, requires administrative effort | | Greenlight's eCOA Solution | Most clinical trials | Pre‑built library, automated workflows, integration with eConsent and devices | | Third‑party eCOA Solution | Organizations with existing eCOA systems | Custom integration with existing platforms |
The IWQOL-Lite-CT was developed to provide a more focused and efficient tool compared to its predecessors. It consists of 20 items across several domains that are directly impacted by an individual's weight. This tool is particularly valuable in clinical trials for assessing the efficacy of weight loss interventions beyond just weight loss itself, focusing on how these interventions improve or affect patients' quality of life.
Specifically optimized for clinical trials by standardizing language, improving sensitivity to therapeutic changes, and meeting stringent regulatory guidelines set by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Core Domains and Structure This structure gives researchers a two-level view: a
The instrument is highly sensitive to small, clinically meaningful changes in weight. When patients lose as little as 5% to 10% of their body weight, the IWQOL-Lite-CT accurately reflects corresponding improvements in physical capabilities and emotional health. 3. Standardized Benchmarking
Is your project an or a commercial/industry trial ?